(Q41219022)

28 September 2017

1 reference

title

Monocyte deactivation--rationale for a new therapeutic strategy in sepsis (English)

1 reference

28 September 2017

0 references

H D Volk

1

1 reference

28 September 2017

P Reinke

2

1 reference

28 September 2017

D Krausch

3

1 reference

28 September 2017

H Zuckermann

4

1 reference

28 September 2017

K Asadullah

5

1 reference

28 September 2017

J M Müller

6

1 reference

28 September 2017

W D Döcke

7

1 reference

28 September 2017

W J Kox

8

1 reference

28 September 2017

publication date

1 October 1996

1 reference

28 September 2017

published in

Intensive Care Medicine

1 reference

28 September 2017

volume

22 Suppl 4

1 reference

28 September 2017

page(s)

S474-81

1 reference

Septic shock: pathogenesis

28 September 2017

cites work

1 reference

12 December 2020

Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis

1 reference

12 December 2020

Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide.

1 reference

12 December 2020

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

12 December 2020

From the Centers for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia--United States, 1979-1987

1 reference

12 December 2020

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

12 December 2020

The role of tumor necrosis factor in sepsis

1 reference

12 December 2020

Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta

1 reference

12 December 2020

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

1 reference

12 December 2020

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1 reference

12 December 2020

Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease

1 reference

12 December 2020

Cytokines yes, cytokines no, cytokines maybe?

1 reference

12 December 2020

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

12 December 2020

Interleukin 10 protects mice from lethal endotoxemia

1 reference

12 December 2020

Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia

1 reference

12 December 2020

Immunodepression following neurosurgical procedures.

1 reference

12 December 2020

Lipopolysaccharide‐induced interleukin‐10 in mice: role of endogenous tumor necrosis factor‐α

1 reference

12 December 2020

Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha

1 reference

12 December 2020

Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01743727

1 reference

28 September 2017

1 reference